These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31854124)

  • 41. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.
    Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L
    ACS Chem Neurosci; 2023 Nov; 14(21):3928-3940. PubMed ID: 37847546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020).
    Groth O; Roider G; Angerer V; Schäper J; Graw M; Musshoff F; Auwärter V
    Int J Legal Med; 2023 Jul; 137(4):1059-1069. PubMed ID: 37072496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.
    Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR
    Drug Test Anal; 2019 Feb; 11(2):279-291. PubMed ID: 30151911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists.
    Wouters E; Walraed J; Banister SD; Stove CP
    Biochem Pharmacol; 2019 Nov; 169():113623. PubMed ID: 31472128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
    Finlay DB; Manning JJ; Ibsen MS; Macdonald CE; Patel M; Javitch JA; Banister SD; Glass M
    ACS Chem Neurosci; 2019 Oct; 10(10):4350-4360. PubMed ID: 31513380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new cannabinoid receptor 1 selective agonist evading the 2021 "China ban": ADB-FUBIATA.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1639-1644. PubMed ID: 35570246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists.
    Pulver B; Riedel J; Schönberger T; Halter S; Lucas T; Opatz T; Grafinger KE; Scheu M; Zschiesche A; Pütz M; Pützer K; Westphal F; Auwärter V
    Drug Test Anal; 2023 Apr; 15(4):408-425. PubMed ID: 36541839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
    Malaca S; Tini A; Umani Ronchi F
    Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting.
    May B; Naqi HA; Tipping M; Scott J; Husbands SM; Blagbrough IS; Pudney CR
    Anal Chem; 2019 Oct; 91(20):12971-12979. PubMed ID: 31580647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro cannabinoid receptor activity, metabolism, and detection in seized samples of CH-PIATA, a new indole-3-acetamide synthetic cannabinoid.
    Norman C; Deventer MH; Dremann O; Reid R; Van Uytfanghe K; Guillou C; Vinckier IMJ; Nic Daéid N; Krotulski A; Stove CP
    Drug Test Anal; 2024 Apr; 16(4):380-391. PubMed ID: 37491777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Linking in vitro and ex vivo CB
    Janssens LK; Hudson S; Wood DM; Wolfe C; Dargan PI; Stove CP
    Arch Toxicol; 2022 Nov; 96(11):2935-2945. PubMed ID: 35962200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
    Hobbs M; Kalk NJ; Morrison PD; Stone JM
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism.
    Gavryushov S; Bashilov A; Cherashev-Tumanov KV; Kuzmich NN; Burykina TI; Izotov BN
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
    Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
    Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018.
    Finlay DB; Nguyen T; Gamage TF; Chen S; Barrus DG; Patel PR; Thomas BF; Wiley JL; Zhang Y; Glass M
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00901. PubMed ID: 35041297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
    Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
    Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
    Smith KE; Staton M
    Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.